| 1 | dose | 50,318 |
| 2 | molecular-weight | 19 |
| 3 | dosis | 12 |
| 4 | sacrectomy | 10 |
| 5 | amount-high | 8 |
| 6 | starting-dose | 7 |
| 7 | extravagance | 4 |
| 8 | agent- | 3 |
| 9 | amount-moderate | 3 |
| 10 | drug-dose | 3 |
| 11 | gaba/kg | 3 |
| 12 | gamma-value | 3 |
| 13 | log-dose | 3 |
| 14 | q1m | 3 |
| 15 | sst2/high-dose | 3 |
| 16 | 133xenon | 2 |
| 17 | days- | 2 |
| 18 | gulp | 2 |
| 19 | risk/cvd | 2 |
| 20 | sst2/low-dose | 2 |
| 21 | target-concentration | 2 |
| 22 | +clarithromycin | 1 |
| 23 | +tinidazole | 1 |
| 24 | 30-300n | 1 |
| 25 | bi-plot | 1 |
| 26 | depth-of-anaesthesia | 1 |
| 27 | dose/75-mg/day | 1 |
| 28 | dose/concentration | 1 |
| 29 | doses/slower | 1 |
| 30 | effect-that | 1 |
| 31 | femtomolar | 1 |
| 32 | group-receiving | 1 |
| 33 | high-pressure-treatment | 1 |
| 34 | immunolgically | 1 |
| 35 | inr-monitored | 1 |
| 36 | oncology-phoenix | 1 |
| 37 | oral-medication | 1 |
| 38 | pulse/respiratory | 1 |
| 39 | rct.there | 1 |
| 40 | risk-treated | 1 |
| 41 | risk/high | 1 |
| 42 | scolopidium | 1 |
| 43 | seroprotection/seropositivity/vaccine | 1 |
| 44 | trueone | 1 |
| 1 | +clarithromycin | 1 |
| 2 | +tinidazole | 1 |
| 3 | 133xenon | 2 |
| 4 | 30-300n | 1 |
| 5 | agent- | 3 |
| 6 | amount-high | 8 |
| 7 | amount-moderate | 3 |
| 8 | bi-plot | 1 |
| 9 | days- | 2 |
| 10 | depth-of-anaesthesia | 1 |
| 11 | dose | 50,318 |
| 12 | dose/75-mg/day | 1 |
| 13 | dose/concentration | 1 |
| 14 | doses/slower | 1 |
| 15 | dosis | 12 |
| 16 | drug-dose | 3 |
| 17 | effect-that | 1 |
| 18 | extravagance | 4 |
| 19 | femtomolar | 1 |
| 20 | gaba/kg | 3 |
| 21 | gamma-value | 3 |
| 22 | group-receiving | 1 |
| 23 | gulp | 2 |
| 24 | high-pressure-treatment | 1 |
| 25 | immunolgically | 1 |
| 26 | inr-monitored | 1 |
| 27 | log-dose | 3 |
| 28 | molecular-weight | 19 |
| 29 | oncology-phoenix | 1 |
| 30 | oral-medication | 1 |
| 31 | pulse/respiratory | 1 |
| 32 | q1m | 3 |
| 33 | rct.there | 1 |
| 34 | risk-treated | 1 |
| 35 | risk/cvd | 2 |
| 36 | risk/high | 1 |
| 37 | sacrectomy | 10 |
| 38 | scolopidium | 1 |
| 39 | seroprotection/seropositivity/vaccine | 1 |
| 40 | sst2/high-dose | 3 |
| 41 | sst2/low-dose | 2 |
| 42 | starting-dose | 7 |
| 43 | target-concentration | 2 |
| 44 | trueone | 1 |
| 1 | days- | 2 |
| 2 | agent- | 3 |
| 3 | depth-of-anaesthesia | 1 |
| 4 | inr-monitored | 1 |
| 5 | risk-treated | 1 |
| 6 | risk/cvd | 2 |
| 7 | extravagance | 4 |
| 8 | +tinidazole | 1 |
| 9 | seroprotection/seropositivity/vaccine | 1 |
| 10 | trueone | 1 |
| 11 | rct.there | 1 |
| 12 | dose | 50,318 |
| 13 | starting-dose | 7 |
| 14 | log-dose | 3 |
| 15 | drug-dose | 3 |
| 16 | sst2/high-dose | 3 |
| 17 | sst2/low-dose | 2 |
| 18 | amount-moderate | 3 |
| 19 | gamma-value | 3 |
| 20 | gaba/kg | 3 |
| 21 | group-receiving | 1 |
| 22 | amount-high | 8 |
| 23 | risk/high | 1 |
| 24 | q1m | 3 |
| 25 | scolopidium | 1 |
| 26 | 30-300n | 1 |
| 27 | +clarithromycin | 1 |
| 28 | oral-medication | 1 |
| 29 | target-concentration | 2 |
| 30 | dose/concentration | 1 |
| 31 | 133xenon | 2 |
| 32 | gulp | 2 |
| 33 | femtomolar | 1 |
| 34 | doses/slower | 1 |
| 35 | dosis | 12 |
| 36 | effect-that | 1 |
| 37 | molecular-weight | 19 |
| 38 | high-pressure-treatment | 1 |
| 39 | bi-plot | 1 |
| 40 | oncology-phoenix | 1 |
| 41 | dose/75-mg/day | 1 |
| 42 | immunolgically | 1 |
| 43 | sacrectomy | 10 |
| 44 | pulse/respiratory | 1 |